Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

2844 - Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers

Date

29 Sep 2019

Session

Poster Display session 2

Topics

Tumour Site

Ovarian Cancer

Presenters

S.Intidhar Labidi-Galy

Citation

Annals of Oncology (2019) 30 (suppl_5): v403-v434. 10.1093/annonc/mdz250

Authors

S.I. Labidi-Galy1, T. de La Motte Rouge2, O. Derbel3, A. Wolfer4, E. Kalbacher5, T. Olivier6, J. Combes7, K. Hu-Heimgartner1, O. Tredan8, H. Guevara8, V. Heinzelmann-Schwarz9, M. Fehr10, V. de Castelbajac11, P. Vaflard12, L. Crivelli13, V. Bonadona8, V. Viassolo1, F. Bazan14, M. Rodrigues12, I.L. Ray-Coquard8

Author affiliations

  • 1 Depatment Of Oncology, Hôpitaux Universitaires de Genève - HUG, 1211 - Geneva/CH
  • 2 Department Of Medical Oncology, Centre Eugene - Marquis, 35042 - Rennes/FR
  • 3 Institut Du Cancer, Hôpital prive Jean mermoz, 69008 - Lyon/FR
  • 4 Department Of Oncology, CHUV - Centre Hospitalier Universitaire Vaudois, 1011 - Lausanne/CH
  • 5 Department Of Oncology, CHRU Besancon - Hopital Jean Minjoz, 25030 - Besançon/FR
  • 6 Department Of Oncology, Hôpitaux Universitaires de Genève - HUG, 1211 - Geneva/CH
  • 7 Infections And Cancer Epidemiology Group, IARC, 69003 - Lyon/FR
  • 8 Department Of Medical Oncology, Centre Léon Bérard, 69008 - Lyon/FR
  • 9 Department Of Gynecology, Universitätsspital Basel, 4031 - Basel/CH
  • 10 Frauenklinik, Kantonsspital Frauenfeld, 8501 - Frauenfeld/CH
  • 11 Department Of Oncology, Institut Curie, 75005 - Paris/FR
  • 12 Department Of Medical Oncology, Institut Curie, 75005 - Paris/FR
  • 13 Ddivision Of Cancer Genetics, Centre Eugene - Marquis, 35042 - Rennes/FR
  • 14 Doubs, CHU Besançon, Hôpital Jean Minjoz, 25030 - Besançon/FR

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2844

Background

To investigate clinical factors associated with prolonged progression-free survival (PFS) and overall survival (OS) in relapsing epithelial ovarian cancer (EOC) patients with BRCA mutations and receiving olaparib as maintenance therapy in real-world.

Methods

Multicenter (8 hospitals) European retrospective study of relapsing EOC patients having germline or somatic mutations of BRCA1/BRCA2 genes and treated with olaparib as maintenance therapy after platinum-based chemotherapy.

Results

One hundred and fifteen patients were included. Median age was 54 years. There were 90 BRCA1 carriers, 24 BRCA2 carriers and one patient had germline mutation of BRCA1 and BRCA2. Six patients had somatic mutations (all BRCA1) and 109 had germline mutations. Ninety percent had serous carcinomas and were platinum-sensitive. Following ultimate platinum-based chemotherapy, 69% of the patients had normalization of CA-125 levels and 87% had RECIST objective responses, either partial (53%) or complete (34%). After a median follow-up of 21 months, median PFS was 12.7 months and median OS was 35.4 months. In multivariate analysis, factors associated with prolonged PFS under olaparib were: platinum-free interval (PFI) ≥ 12 months, RECIST complete response (CR) or partial response (PR) and normalization of CA-125 upon ultimate platinum-based chemotherapy. Factors associated with prolonged OS were PFI ≥ 12 months, CR and normalization of CA-125.

Conclusions

Platinum-free interval ≥ 12 months, complete response and normalized CA-125 levels after ultimate platinum-based chemotherapy are associated with prolonged PFS and OS in relapsing BRCA mutated ovarian cancer patients who received olaparib as maintenance therapy.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

S.I. Labidi-Galy: Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca. T. de La Motte Rouge: Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca. O. Derbel: Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca. A. Wolfer: Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca. E. Kalbacher: Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca. O. Tredan: Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca. V. Heinzelmann-Schwarz: Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca. F. Bazan: Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca. M. Rodrigues: Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca. I.L. Ray-Coquard: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: AstraZeneca. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.